Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

118   -4.17 (-3.41%) 01-19 08:21
Open: 120 Pre. Close: 122.17
High: 120.71 Low: 116.2
Volume: 1,106,075 Market Cap: 7,729M
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 121.498 - 122.664 122.664 - 123.369
Low: 113.745 - 115.255 115.255 - 116.169
Close: 116.262 - 118.73 118.73 - 120.222

Technical analysis

as of: 2022-01-18 4:29:42 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 145.93     One year: 165.27
Support: Support1: 98.16    Support2: 81.67
Resistance: Resistance1: 124.94    Resistance2: 141.50
Pivot: 130.03
Moving Average: MA(5): 123.06     MA(20): 131.05
MA(100): 128.67     MA(250): 106.06
MACD: MACD(12,26): 0.24     Signal(9): 2.24
Stochastic oscillator: %K(14,3): 9.01     %D(3): 11.24
RSI: RSI(14): 40.51
52-week: High: 151.51  Low: 62.57  Change(%): 48.1
Average Vol(K): 3-Month: 60973  10-Days: 82702

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
BHVN has closed above bottom band by 5.8%. Bollinger Bands are 5.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 18 Jan 2022
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma - Yahoo Finance

Mon, 17 Jan 2022
Pfizer: Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States - India Education Diary

Thu, 13 Jan 2022
Will Biohaven Pharmaceutical Holding Co Ltd (BHVN) Beat the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver

Sat, 08 Jan 2022
Broker Revenue Forecasts For Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Are Surging Higher - Nasdaq

Sat, 08 Jan 2022
There's A Lot To Like About Accenture's (NYSE:ACN) Upcoming US$0.97 Dividend - Nasdaq

Wed, 05 Jan 2022
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States - Pfizer

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Underperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Outperform Debt to Equity: Underperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 66
Shares Float (M) 55
% Held by Insiders 12.67
% Held by Institutions 92.82
Shares Short (K) 4,400
Shares Short P. Month (K) 3,450

Stock Financials

EPS -13.700
EPS Est This Year -5.450
EPS Est Next Year -4.390
Book Value (p.s.) -8.980
Profit Margin -281.24
Operating Margin -229.71
Return on Assets (ttm) -46.2
Return on Equity (ttm)
Qtrly Rev. Growth 668.5
Gross Profit (p.s.) 0.701
Sales Per Share 4.696
EBITDA (p.s.) -10.455
Qtrly Earnings Growth
Operating Cash Flow (M) -850
Levered Free Cash Flow (M) -408

Stock Valuations

PE Ratio -8.61
PEG Ratio
Price to Book value -13.14
Price to Sales 25.13
Price to Cash Flow -9.09

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.